Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy

Oncolytic virus (OV) therapy is an emerging cancer treatment that uses replicating viruses to infect and kill tumor cells and incite anticancer immunity. While the approach shows promise, it currently fails most patients, indicating strategies to improve OV activity are needed. Developing these will require greater understanding of OV biology, particularly in the context of OV delivery and clearance, the infection process within a complex tumor microenvironment, and the modulation of anticancer immunity. To help achieve this, we have established a technique for high-resolution 4D imaging of OV-host interactions within intact tissues of live mice using intravital microscopy (IVM). We show that oncolytic vesicular stomatitis virus (VSV) directly labeled with Alexa Fluor dyes is easily visualized by single- or multiphoton microscopy while retaining bioactivity in vivo. The addition of fluorophore-tagged antibodies and genetically encoded reporter proteins to image target cells and the virus infection enables real-time imaging of dynamic interactions between VSV and host cells in blood, tumor, and visceral organs of live mice. The method has sufficient in vivo resolution to observe leukocytes in blood binding to and transporting VSV particles, foci of VSV infection spreading through a tumor, and antigen-presenting cells in the spleen interacting with and being infected by VSV. Visualizing OV-host interactions by IVM represents a powerful new tool for studying OV therapy.

[1]  J. Yewdell,et al.  From optical bench to cageside: intravital microscopy on the long road to rational vaccine design , 2011, Immunological reviews.

[2]  Justin M. Richner,et al.  Age-Dependent Cell Trafficking Defects in Draining Lymph Nodes Impair Adaptive Immunity and Control of West Nile Virus Infection , 2015, PLoS pathogens.

[3]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[4]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[5]  D. Nayak,et al.  Visualization of Intracellular Transport of Vesicular Stomatitis Virus Nucleocapsids in Living Cells , 2006, Journal of Virology.

[6]  H. Atkins,et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.

[7]  J. Brunschwig,et al.  Biophysical Studies of Vesicular Stomatitis Virus , 1966, Journal of bacteriology.

[8]  N. D. Di Paolo,et al.  Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells , 2007, Nature.

[9]  J. Diallo,et al.  Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. , 2012, Methods in molecular biology.

[10]  S. Russell,et al.  ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.

[11]  Yi Lin,et al.  Surface labeling of enveloped viruses assisted by host cells. , 2012, ACS chemical biology.

[12]  Siamon Gordon,et al.  Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes , 2010, Nature Immunology.

[13]  Liang Zhang,et al.  Maraba virus as a potent oncolytic vaccine vector. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  M. Whitt,et al.  A Spatio-Temporal Analysis of Matrix Protein and Nucleocapsid Trafficking during Vesicular Stomatitis Virus Uncoating , 2010, PLoS pathogens.

[15]  V. Naumenko,et al.  Intravital Microscopy for Imaging the Tumor Microenvironment in Live Mice. , 2016, Methods in molecular biology.

[16]  A. Werman,et al.  LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus , 2013, Proceedings of the National Academy of Sciences.

[17]  G. McFadden,et al.  Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. , 2013, Cell host & microbe.

[18]  Nathan M. Sherer,et al.  Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells , 2005, The Journal of cell biology.

[19]  M. S. Gonçalves,et al.  Fluorescent labeling of biomolecules with organic probes. , 2009, Chemical reviews.

[20]  H. Ishigame,et al.  In vivo multiphoton imaging of immune cell dynamics , 2016, Pflügers Archiv - European Journal of Physiology.

[21]  L. Diehl,et al.  CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens , 2006, Cell.

[22]  Hayo Castrop,et al.  Deep insights: intravital imaging with two-photon microscopy , 2016, Pflügers Archiv - European Journal of Physiology.

[23]  D. Kreisel,et al.  Intravital 2-photon imaging, leukocyte trafficking, and the beating heart. , 2013, Trends in cardiovascular medicine.

[24]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[25]  H. Atkins,et al.  Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  J. Yewdell,et al.  Caught in the act: intravital multiphoton microscopy of host-pathogen interactions. , 2009, Cell host & microbe.

[27]  Debasis Panda,et al.  Biarsenical Labeling of Vesicular Stomatitis Virus Encoding Tetracysteine-Tagged M Protein Allows Dynamic Imaging of M Protein and Virus Uncoating in Infected Cells , 2009, Journal of Virology.

[28]  Jacco van Rheenen,et al.  Imaging hallmarks of cancer in living mice , 2014, Nature Reviews Cancer.

[29]  Sandeep T. Koshy,et al.  Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination , 2016, The Journal of Immunology.

[30]  S. Russell,et al.  Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions. , 2011, Journal of virological methods.

[31]  Y. Toiyama,et al.  In vivo optical imaging of cancer metastasis using multiphoton microscopy: a short review. , 2014, American journal of translational research.

[32]  G. Linette,et al.  Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  M. Whitt,et al.  Glycoprotein-Dependent Acidification of Vesicular Stomatitis Virus Enhances Release of Matrix Protein , 2009, Journal of Virology.

[34]  M. Ramakrishnan.  Determination of 50% endpoint titer using a simple formula. , 2016, World journal of virology.

[35]  J. Peti-Peterdi,et al.  Novel in vivo techniques to visualize kidney anatomy and function , 2015, Kidney international.

[36]  S. Russell,et al.  Vesiculovirus Neutralization by Natural IgM and Complement , 2014, Journal of Virology.

[37]  X. Zhuang,et al.  Virus trafficking – learning from single-virus tracking , 2007, Nature Reviews Microbiology.

[38]  K. Klingel,et al.  Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus , 2011, Nature Immunology.

[39]  H. Atkins,et al.  Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  G. McFadden,et al.  Viruses for tumor therapy. , 2014, Cell host & microbe.

[41]  Eleanor Pullenayegum,et al.  Potentiating cancer immunotherapy using an oncolytic virus. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Javier G. Magadán,et al.  Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. , 2013, Cell host & microbe.

[43]  Yi Lin,et al.  Labeling the nucleocapsid of enveloped baculovirus with quantum dots for single-virus tracking. , 2014, Biomaterials.

[44]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Alain,et al.  Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. , 2011, Cancer cell.

[46]  Philippe Bousso,et al.  Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. , 2008, The Journal of clinical investigation.

[47]  J. Boudreau,et al.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  M. Coffey,et al.  Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Andrew D. Luster,et al.  HIV-infected T cells are migratory vehicles for viral dissemination , 2012, Nature.

[50]  B. Lichty,et al.  Combining oncolytic virotherapy and tumour vaccination. , 2010, Cytokine & growth factor reviews.

[51]  Christoph J. Burckhardt,et al.  Virus Movements on the Plasma Membrane Support Infection and Transmission between Cells , 2009, PLoS pathogens.

[52]  J. Boudreau,et al.  Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. , 2013, Blood.

[53]  I. Melero,et al.  Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb , 2015, Proceedings of the National Academy of Sciences.